Fake compounded GLP-1 drugs: how to check the label and pharmacy

01

What FDA has reported about fraudulent compounded GLP-1 products

FDA's current consumer page says it is aware of fraudulent compounded semaglutide and tirzepatide marketed in the United States with false label information. In some cases the named compounding pharmacy did not exist. In others, a real licensed pharmacy told FDA it had not compounded the product bearing its name. FDA also describes one adverse-event report involving a product labeled as compounded tirzepatide from a pharmacy that did not actually make it.

That record does not establish how common fraudulent products are, and one report cannot establish that a product caused the reported reaction. It does establish a practical limitation: label text alone cannot authenticate a vial. A consumer needs to connect the physical product to a real prescription, dispensing record, pharmacy, and lot.

Keep categories straight. A fraudulent compounded product may falsely claim a compounding source. A counterfeit approved drug is passed off as an authentic approved brand. A legitimate compounded drug is still not FDA-approved. Each category requires accurate language because approval status, supply chain, and reporting questions differ.

02

Pause before use when the product identity is uncertain

FDA lists spelling mistakes, incorrect pharmacy addresses, unexpected appearance, broken or damaged packaging, missing directions, and prices that seem too good to be true among warning signs. A difference does not prove fraud: pharmacies can change packaging, and compounded preparations can differ. But an unexplained mismatch should be resolved before the product is used.

Do not taste, inject, reconstitute, or otherwise test a suspect product yourself. Do not rely on a seller's assurance that a purity result or QR code proves authenticity. A certificate can be copied or attached to the wrong lot, and a QR code can point to content controlled by the seller.

If a product arrived warm when its written instructions require refrigeration, is visibly damaged or discolored, lacks a complete patient label, or cannot be matched to the prescription, isolate it from other medication. Ask the dispensing pharmacy how to preserve it while the identity or quality concern is investigated.

03

Verify the pharmacy through an independent path

Start with the legal pharmacy name and physical address printed on the patient label. Search the relevant state board of pharmacy rather than a general web result. Match the license holder, address, license type, current status, and any authority needed to dispense into the patient's state. A similar trade name or different location is not an exact match.

Obtain the pharmacy's phone number from the official license record or the pharmacy's independently located website, not solely from the suspicious package. Ask whether the pharmacy dispensed the prescription, whether the lot and label format are theirs, and whether the prescriber's information matches their record. The pharmacy may need identifying details to investigate, but consumers should avoid sending health information through unverified email or messaging accounts.

Also verify the prescriber through the applicable professional licensing board and contact the clinic through a known channel. The clinic should be able to name the pharmacy, explain the dispensing pathway, and reconcile the order without treating basic product-source questions as proprietary.

• →Exact pharmacy legal name and address
• →Current board-of-pharmacy record
• →Prescription or order identifier
• →Product name and labeled strength
• →Lot and beyond-use date
• →Package and label photographs
• →Independent pharmacy and prescriber confirmation

04

Preserve useful evidence without handling the product unnecessarily

Save the shipping box, insulated packaging, patient label, vial or pen carton, receipts, order confirmations, and communications. Photograph every side of the unopened product and package, including lot numbers, dates, pharmacy information, damage, and temperature indicators. Record when the delivery arrived and how it was stored afterward.

FDA's MedWatch instructions emphasize the manufacturer or compounder, product name, labeled strength, lot number, and packaging for product-quality reports. A precise timeline and clear images are more useful than a conclusion such as fake or contaminated that has not been established by testing.

Do not mail a sample to FDA unless the agency specifically requests it. FDA's reporting materials say product availability and photographs can be noted in a report; the agency may follow up if examination is needed. Ask the pharmacy how to store a suspect product and keep it away from children or anyone who might use it accidentally.

05

Choose the right reporting route

A serious reaction, medication error, suspected quality defect, labeling problem, or therapeutic failure can be reported through MedWatch. Consumers can use Form 3500B. A report is a safety signal, not proof that the product caused an event, and FDA encourages identifying details that let reviewers match the report to a product and source.

FDA provides a separate route for reporting unlawful internet sales of medical products. Suspected criminal counterfeit activity can also be directed to FDA's Office of Criminal Investigations. A state board of pharmacy may accept complaints about a pharmacy or someone impersonating one. These paths can overlap, and filing one does not replace urgent medical evaluation.

Contact the pharmacy and prescribing clinician promptly, but do not let a seller discourage an FDA or board report. If symptoms are severe or rapidly worsening, seek emergency or urgent care as appropriate. This guide cannot determine whether a reaction is caused by the product or advise whether a legitimate prescription should be continued.

06

Provider warning signs after a label concern

A responsible provider should identify the prescribing clinician and dispensing pharmacy, document the complaint, help reconcile the lot, and give a clear route for pharmacy and clinical follow-up. The provider should not replace the pharmacy's identity with its own brand or claim that FDA registration, 503B registration, accreditation, or third-party testing guarantees the product.

Be cautious when a platform will communicate only by direct message, refuses to name the pharmacy, produces a new label image instead of confirming the actual lot, asks the consumer to discard all packaging immediately, or insists that the product is generic or the same as an FDA-approved drug. Those responses prevent independent verification.

The safest research conclusion may be unresolved. If the pharmacy cannot authenticate the item, treat that uncertainty as material and follow instructions from a licensed clinician and pharmacist. A directory profile, positive review, or low price cannot substitute for product-level confirmation.